TICKERNERD
Menu
ESPRESPRHealthcare · Drug Manufacturers - Specialty & Generic

ESPR Stock Forecast: Esperion Therapeutics, Inc. Price Predictions for 2026-2027

Market cap
$819.5M
Ticker Nerd rank
—
Median analyst target
$3.16
Analysts covering
5
Revenue$80.1M+23.2% y/y
Operating income−$6.6M
Net income−$25.2M
Free cash flow−$27.9M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Ticker Nerd rank

ESPR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Esperion Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

We don’t hold a current model rank for this company.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ESPR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ESPR, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says5 analysts
0 Buy5 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 May 2026NeedhamDowngradeHold—
1 May 2026HC Wainwright & Co.DowngradeNeutral$3.16
13 Mar 2026CitizensMaintainsMarket Outperform—
3 Mar 2026NeedhamMaintainsBuy—
25 Nov 2025Piper SandlerInitiatesOverweight—
19 Sept 2025HC Wainwright & Co.ReiteratesBuy—
17 June 2025HC Wainwright & Co.ReiteratesBuy—
7 May 2025NeedhamMaintainsBuy—
25 Apr 2025HC Wainwright & Co.ReiteratesBuy—
25 Apr 2025NeedhamReiteratesBuy—
17 Apr 2025Goldman SachsMaintainsNeutral—
8 Apr 2025NeedhamReiteratesBuy—
20 Mar 2025HC Wainwright & Co.ReiteratesBuy—
5 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform—
4 Mar 2025HC Wainwright & Co.ReiteratesBuy—
11 Feb 2025HC Wainwright & Co.ReiteratesBuy—
11 Feb 2025JMP SecuritiesReiteratesMarket Outperform—
23 Jan 2025HC Wainwright & Co.ReiteratesBuy—
23 Jan 2025JMP SecuritiesReiteratesMarket Outperform—
22 Jan 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ESPR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ESPR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−1675.4%
Analysts raising
1
Analysts cutting
0
Fundamentals

Esperion Therapeutics, Inc. (ESPR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−28.9×

Cheaper than 97% of US stocks

Price / sales
2.0×

Cheaper than 52% of US stocks

Price / book
−2.6×

Cheaper than 96% of US stocks

EV / EBITDA
15.9×

Cheaper than 21% of US stocks

Growth & margins
Revenue growth (YoY)
23.2%

Higher than 72% of US stocks

Earnings growth (YoY)
23.2%

Higher than 61% of US stocks

Gross margin
56.8%

Higher than 70% of US stocks

Operating margin
−8.2%

Higher than 25% of US stocks

Net margin
−1.8%

Higher than 28% of US stocks

Returns & dividend
Return on equity
7.5%

Higher than 58% of US stocks

Return on assets
12.0%

Higher than 95% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Esperion Therapeutics, Inc. (ESPR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Esperion Therapeutics, Inc. has a market value of $819.5M and an enterprise value of $1.2B.

  • Revenue in the twelve months to 31 Mar 2026: $418.2M. The latest quarter grew 23.2% year on year.

  • Net income over the same four quarters: −$7.4M, a −1.8% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.06.

  • Free cash flow in the twelve months to 31 Mar 2026: −$18.4M, after $189K of capital spending.

  • Shares outstanding: 257.4M.

  • Trailing P/E: −28.9×; forward P/E: 12.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Esperion Therapeutics, Inc. employs 294 people — $1.4M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 11 Aug 2026

Data provided by Twelve Data

Peers

ESPR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ESPREsperion Therapeutics, Inc.$819.5M
—
LLYEli Lilly & Co.*$1.1T
83
JNJJohnson & Johnson*$611.9B
76
ABBVAbbVie, Inc.*$500.9B
94
MRKMerck & Co., Inc.*$365.8B
81
UNHUnitedHealth Group, Inc.*$358.4B
78
TMOThermo Fisher Scientific, Inc.*$252.9B
84

* Nearest Healthcare names by size — few drug manufacturers - specialty & generic companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Esperion Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ESPR news & analysis

Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040

GlobeNewsWire · 7 Oct 2026positive

Esperion announced a settlement with Renata Limited and an affiliate resolving patent litigation over their ANDAs for generic NEXLETOL and NEXLIZET. Under the agreement, Renata will not market either generic in the United States before April 19, 2040, except in certain limited circumstances.

Why it matters — The settlement sets out when Renata may begin U.S. generic marketing of the two products, subject to the agreement’s stated exceptions.

FAQ

Frequently asked questions about ESPR stock

What is the ESPR stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Esperion Therapeutics, Inc. have a median 12-month price target of $3.16, with estimates ranging from $3.16 to $3.28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ESPR stock a buy right now?

Of the 5 analysts covering Esperion Therapeutics, Inc., 0 rate it a Buy, 5 a Hold and 0 a Sell. None of this is personal advice — it does not consider your circumstances.

Will ESPR stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies from the last close. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ESPR stock forecast for 2030?

No analyst covering Esperion Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ESPR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.16 to $3.28 over the next 12 months.

What does Esperion Therapeutics, Inc. do?

Esperion Therapeutics Inc. is a pharmaceutical company that develops and commercializes oral, once-daily, non-statin medicines designed for patients with elevated low-density lipoprotein cholesterol.

What is the latest news on ESPR?

The most recent item we track (GlobeNewsWire, 7 Oct 2026): "Esperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040". Esperion announced a settlement with Renata Limited and an affiliate resolving patent litigation over their ANDAs for generic NEXLETOL and NEXLIZET. Under the agreement, Renata will not market either generic in the United States before April 19, 2040, except in certain limited circumstances.

Company

About Esperion Therapeutics, Inc.

Esperion Therapeutics Inc. is a pharmaceutical company that develops and commercializes oral, once-daily, non-statin medicines designed for patients with elevated low-density lipoprotein cholesterol. The company's primary marketed products are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which serve patients with primary hyperlipidemia, including those with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional LDL-C lowering. These therapies address patients who are statin-intolerant or require supplementary cholesterol management beyond traditional treatments. Esperion has expanded its global reach through partnerships, with its bempedoic acid products now available in markets including Japan and Canada. The company operates in the cardiovascular health segment, focusing on closing treatment gaps in dyslipidemia management. Founded in 1998 and headquartered in Ann Arbor, Michigan, Esperion operates as a commercial-stage biopharmaceutical company dedicated to advancing treatment options for patients with elevated cholesterol and related cardiovascular risk factors.

CEO Mr. Sheldon L. Koenig M.B.A. · 294 employees · United States · https://www.esperion.com